scholarly journals Phosphorylation in situ of atrial natriuretic peptide prohormone at the cyclic AMP-dependent site.

1988 ◽  
Vol 263 (8) ◽  
pp. 3778-3783
Author(s):  
J Rittenhouse ◽  
L Moberly ◽  
H Ahmed ◽  
F Marcus
1989 ◽  
Vol 13 ◽  
pp. S36-S38 ◽  
Author(s):  
Satoshi Umemura ◽  
Yoshiyuki Toya ◽  
Nobuhito Hirawa ◽  
Yoshihiro Ishikawa ◽  
Kosuke Minamizawa ◽  
...  

FEBS Letters ◽  
1987 ◽  
Vol 224 (2) ◽  
pp. 325-330 ◽  
Author(s):  
Gillian M. Olins ◽  
Pramod P. Mehta ◽  
Delores J. Blehm ◽  
Dennis R. Patton ◽  
Mark E. Zupec ◽  
...  

1994 ◽  
Vol 12 (2) ◽  
pp. 149-154
Author(s):  
W J Burgess ◽  
M N Perrott ◽  
R J Balment

ABSTRACT It is unclear whether the diuretic effects of atrial natriuretic peptide (ANP) result, in part, from an inhibition of the renal actions of vasopressin. Moreover, accruing evidence suggests that the kidneys themselves may produce an ANP-like peptide, urodilatin, which shares many of the renal actions of ANP. The mechanism underlying the diuretic action of urodilatin has not yet been examined. Accordingly, we have investigated the potential modulatory actions of both ANP and urodilatin on vasopressin-stimulated cyclic AMP (cAMP) production in microdissected inner medullary collecting duct (IMCD) segments of rat kidney. ANP and urodilatin alone (at 10−8 or 10−6 m) had no demonstrable effect on cAMP accumulation in IMCD segments. Moreover, neither ANP nor urodilatin (each at 10−6 m) significantly altered either the profile or the absolute magnitude of the cAMP response stimulated by vasopressin. These findings indicate that neither ANP nor urodilatin interacts with the vasopressin-sensitive adenylate cyclase site in the rat IMCD to contribute to its diuretic actions.


1993 ◽  
Vol 100 (4) ◽  
pp. 277-283 ◽  
Author(s):  
Wen Qin Cai ◽  
Giorgio Terenghi ◽  
Philippe Bodin ◽  
Geoffrey Burnstock ◽  
Julia M. Polak

1988 ◽  
Vol 13 ◽  
pp. S36-S38 ◽  
Author(s):  
Satoshi Umemura ◽  
Yoshiyuki Toya ◽  
Nobuhito Hirawa ◽  
Yoshihiro Ishikawa ◽  
Kosuke Minamizawa ◽  
...  

Life Sciences ◽  
1990 ◽  
Vol 47 (22) ◽  
pp. 2027-2033 ◽  
Author(s):  
Richard E. Klabunde ◽  
Mary C. Helgren ◽  
Eugene I. Novosad ◽  
Terry J. Opgenorth

1990 ◽  
Vol 258 (2) ◽  
pp. H521-H528 ◽  
Author(s):  
D. J. Meyer ◽  
V. H. Huxley

Acute plasma volume reduction by atrial natriuretic peptide (ANP) may be mediated, at least in part, by increased exchange vessel water conductivity (Lp). The present study tests the hypothesis that physiological levels of ANP acutely and reversibly elevate single capillary Lp. Paired, in situ measurements of Lp were obtained using the modified Landis technique in individually perfused mesenteric capillaries of the frog, Rana pipiens. Control Lp measurements ranged from 0.1 to 40 x 10(-7) cm.s-1.cmH2O-1 (with a median value of 2.5 x 10(-7] in 81 microvessels perfused with frog Ringer solution containing dialyzed bovine serum albumin. Vessels were recannulated and perfused with one or more concentrations of human ANP (hANP) spanning the physiopathological range: 0.01, 0.1, 1, 10, and 100 nM. When possible, a final recannulation and Lp determination was performed in the absence of hANP. A median 2.2-fold rapid Lp increase was observed compared with control at each peptide concentration. Lp changes persisted for the duration of exposure to hANP, returning to control levels on withdrawal of the peptide. True and venular capillaries exhibited similar Lp responses: median 2.2- and 2.4-fold elevations, respectively. Sixty percent of true and venular capillaries exhibited twofold or greater hANP-induced increases in Lp, whereas only 25% of arteriolar capillaries exhibited such a response. Thus a differential sensitivity to the peptide exists across the exchange vessel network. The observations of this study demonstrate that physiological levels of ANP are capable of modulating exchange vessel Lp, one means by which the peptide may acutely alter plasma volume.(ABSTRACT TRUNCATED AT 250 WORDS)


Sign in / Sign up

Export Citation Format

Share Document